Perspectives in understanding the role of human 17β-hydroxysteroid dehydrogenases in health and disease

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 15-24

  Meier, Marc ^a   Möller, Gabriele ^a   Adamski, Jerzy ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

17 hydroxysteroid dehydrogenase (17 HSD); Human disorders; Steroid metabolism

Indexed keywords

CARBONYL REDUCTASE; FATTY ACID; PHYTOESTROGEN; RETINOID; TESTOSTERONE 17BETA DEHYDROGENASE;

CATALYSIS; CELL MEMBRANE; CONFERENCE PAPER; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE ACTIVITY; GENETIC PREDISPOSITION; HEALTH; HORMONAL REGULATION; HUMAN; NOMENCLATURE; NONHUMAN; PATHOGENESIS; STEROID METABOLISM;

ANIMALIA;

EID: 61649096847     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.03702.x     Document Type: Conference Paper

References (106)

1. Jensen, E.V. & E.R. DeSombre. 1973. Estrogen-receptor interaction. Science 182 : 126 134.
2. Heldring, N. et al. 2007. Estrogen receptors: How do they signal and what are their targets Physiol. Rev. 87 : 905 931.
3. Tchernitchin, A. 1972. Radioautographic study of the effect of estradiol-17, estrone, estriol, progesterone, testosterone and corticosterone on the in vitro uptake of 2,4,6,7- 3 H estradiol-17 by uterine eosinophils of the rat. Steroids 19 : 575 586.
4. Jablonski, E.M. et al. 2003. Estrogen regulation of aquaporins in the mouse uterus: Potential roles in uterine water movement. Biol. Reprod. 69 : 1481 1487.
5. Revankar, C.M. et al. 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 : 1625 1630.
6. Zeillinger, R. et al. 1989. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4 : 109 114.
7. Shou, J. et al. 2004. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 : 926 935.
8. Erben, R.G. et al. 2002. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol. 16 : 1524 1537.
9. Hammes, A. et al. 2005. Role of endocytosis in cellular uptake of sex steroids. Cell 122 : 751 762.
10. Karssen, A.M. et al. 2001. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinol. 142 : 2686 2694.
11. Pizzagalli, F. et al. 2003. Identification of steroid sulfate transport processes in the human mammary gland. J. Clin. Endocrinol. Metab. 88 : 3902 3912.
12. Grube, M. et al. 2006. Modification of OATP2B1-mediated transport by steroid hormones. Mol. Pharmacol. 70 : 1735 1741.
13. Kruh, G.D. et al. 2007. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453 : 675 684.
14. Sun, Y.H. et al. 2006. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J. Androl. 27 : 671 678.
15. Sai, Y. et al. 2006. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34 : 1423 1431.
16. Rothnie, A. et al. 2006. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 281 : 13906 13914.
17. Schnabolk, G.W., G.L. Youngblood & D.H. Sweet. 2006. Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am. J. Physiol. Renal Physiol. 291 : F314 321.
18. Atanasov, A.G. et al. 2004. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 571 : 129 133.
19. Khan, N. et al. 2004. Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch. Biochem. Biophys. 429 : 50 59.
20. Miller, W. 1988. Molecular biology of steroid hormone synthesis. Endocrine Rev. 9 : 295 318.
21. Penning, T.M. 2003. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Hum. Reprod. Update 9 : 193 205.
22. Hyndman, D. et al. 2003. The aldo-keto reductase superfamily homepage. Chem. Biol. Interact. 143-144 : 621 631.
23. Moeller, G. & J. Adamski. 2006. Multifunctionality of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 : 47 55.
24. Penning, T.M. 1997. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocrinol. Rev. 18 : 281 305.
25. Penning, T.M. et al. 2008. Pre-receptor regulation of the androgen receptor. Mol. Cell. Endocrinol. 281 : 1 8.
26. Deluca, D. et al. 2004. Biochemical genetics of 17beta-hydroxysteroid dehydrogenases. Curr. Topics Steroid Res. 4 : 227 242.
27. Peltoketo, H., P. Vihko & R. Vihko. 1999. Regulation of estrogen action: Role of 17 beta-hydroxysteroid dehydrogenases. Vitam. Horm. 55 : 353 398.
28. Mindnich, R., G. Möller & J. Adamski. 2004. The role of 17 beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 218 : 7 20.
29. Vihko, P. et al. 2006. Control of cell proliferation by steroids: The role of 17HSDs. Mol. Cell. Endocrinol. 248 : 141 148.
30. Payne, A.H. & D.B. Hales. 2004. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 25 : 947 970.
31. Su, J., M. Lin & J.L. Napoli. 1999. Complementary deoxyribonucleic acid cloning and enzymatic characterization of a novel 17beta/3alpha- hydroxysteroid/retinoid short chain dehydrogenase/reductase. Endocrinol. 140 : 5275 5284.
32. Brereton, P. et al. 2001. Pan1b (17betaHSD11): Enzymatic activity and distribution in the lung. Mol. Cell. Endocrinol. 171/2 : 111 118.
33. Horiguchi, Y., M. Araki & K. Motojima. 2008. 17beta-hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein. Biochem. Biophys. Res. Commun. 370 : 235 238.
34. Belyaeva, O.V. & N.Y. Kedishvili. 2006. Comparative genomic and phylogenetic analysis of short-chain dehydrogenases/reductases with dual retinol/sterol substrate specificity. Genomics 88 : 820 830.
35. Pletnev, V.Z. & W.L. Duax. 2005. Rational proteomics IV: Modeling the primary function of the mammalian 17beta-hydroxysteroid dehydrogenase type 8. J. Steroid Biochem. Mol. Biol. 94 : 327 335.
36. Moon, Y.A. & J.D. Horton. 2003. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J. Biol. Chem. 278 : 7335 7343.
37. Shafquat, N. et al. 2003. Expanded substrate screenings of human and Drosophila type 10 17β-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: Characterization of multifunctional 3α/7α/7β/17β/20β/21-HSD. Biochem. J. 376 : 49 60.
38. Ryan, K.J. & L.L. Engel. 1953. The intercoversion of estrone and estradiol by human tissue slices. Endocrinol. 52 : 287 291.
39. Langer, L.J. & L.L. Engel. 1958. Human placental estradiol-17beta; dehydrogenase. I. Concentration, characterization and assay. J. Biol. Chem. 233 : 583 588.
40. Bruford, E.A. et al. 2008. The HGNC Database in 2008: A resource for the human genome. Nucleic Acids Res. 36 : D445 448.
41. Oppermann, U. et al. 2003. Short-chain dehydrogenases/reductases (SDR): The 2002 update. Chem. Biol. Interact. 143-144 : 247 253.
42. Ofman, R. et al. 2003. 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am. J. Hum. Genet. 72 : 1300 1307.
43. Lenski, C. et al. 2007. The reduced expression of the HADH2 protein causes X-linked mental retardation, choreoathetosis, and abnormal behavior. Am. J. Hum. Genet. 80 : 372 377.
44. Froyen, G. et al. 2008. Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation. Am. J. Hum. Genet. 82 : 432 443.
45. Yang, S.Y., X.Y. He & D. Miller. 2007. HSD17B10: A gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids. Mol. Genet. Metab. 92 : 36 42.
46. Elo, J.P. et al. 1997. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 57 : 3356 3359.
47. Chu, L.W., J.K. Reichardt & A.W. Hsing. 2008. Androgens and the molecular epidemiology of prostate cancer. Curr. Opin. Endocrinol. Diab. Obes. 15 : 261 270.
48. Feigelson, H.S. et al. 2006. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: A comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 66 : 2468 2475.
49. Pollow, K., H. Lubbert & B. Pollow. 1975. Studies on 17 beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. III. Partial purification and characterization of the microsomal enzyme. Acta Endocrinol. (Copenh.) 80 : 355 364.
50. Labrie, F. 1991. Intracrinology. Mol. Cell. Endocrinol. 78 : C113 118.
51. Sasano, H. et al. 2008. Intracrinology of estrogens and androgens in breast carcinoma. J. Steroid Biochem. Mol. Biol. 108 : 181 185.
52. Stanbrough, M. et al. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66 : 2815 2825.
53. Wake, D.J. et al. 2007. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin. Endocrinol. (Oxf.) 66 : 440 446.
54. Steckelbroeck, S. et al. 2006. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J. Pharmacol. Exp. Ther. 316 : 1300 1309.
55. Komoto, J. et al. 2004. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43 : 2188 2198.
56. Oduwole, O.O. et al. 2004. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 64 : 7604 7609.
57. Gunnarsson, C. et al. 2008. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res. Treat. 108 : 35 41.
58. Oduwole, O.O. et al. 2003. 17beta-hydroxysteroid dehydrogenase type 2: Independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. J. Steroid Biochem. Mol. Biol. 87 : 133 140.
59. Rasiah, K.K. et al. 2008. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol. Cell Endocrinol. doi :.
60. Jansson, A., C. Gunnarsson & O. Stal. 2006. Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr. Relat. Cancer 13 : 875 884.
61. Jansson, A.K. et al. 2006. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res. 66 : 11471 11477.
62. Blomquist, C.H. 1995. Kinetic analysis of enzymic activities: Prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 55 : 515 524.
63. Andersson, S. et al. 1996. Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J. Clin. Endocrinol. Metab. 81 : 130 136.
64. Wu, L. et al. 1993. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268 : 12964 12969.
65. Brosic, P., T.L. Risner & S. Gobec. 2008. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem. 15 : 137 150.
66. Poirier, D. 2003. Inhibitors of 17beta-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 : 453 477.
67. Byrns, M.C., S. Steckelbroeck & T.M. Penning. 2008. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75 : 484 493.
68. Lawrence, H.R. et al. 2005. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. J. Med. Chem. 48 : 2759 2762.
69. Tchedam Ngatcha, B. et al. 2005. Androsterone 3alpha-ether-3beta- substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and structure-activity relationship. J. Med. Chem. 48 : 5257 5268.
70. Morrissey, C. & R.W. Watson. 2003. Phytoestrogens and prostate cancer. Curr. Drug Targets 4 : 231 241.
71. Adlercreutz, H. 2002. Phytoestrogens and breast cancer. J. Steroid Biochem. Mol. Biol. 83 : 113 118.
72. Deluca, D. et al. 2005. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: Comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol. 93 : 285 292.
73. Dubey, R.K. et al. 1999. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 33 : 177 182.
74. Tremblay, M.R. et al. 2005. Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: Modifications of the positions 3 and 6 of estradiol. J. Enzyme Inhib. Med. Chem. 20 : 153 163.
75. Poirier, D. et al. 2006. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol. 248 : 236 238.
76. Allan, G.M. et al. 2006. Modification of estrone at the 6, 16, and 17 positions: Novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 49 : 1325 1345.
77. Schwarz, S. et al. 1996. Synthesis of estrogen sulfamates: Compounds with a novel endocrinological profile. Steroids 61 : 710 717.
78. Poirier, D., L.C. Ciobanu & M. Berube. 2002. A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives. Bioorg. Med. Chem. Lett. 12 : 2833 2838.
79. Deluca, D. et al. 2006. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 : 218 224.
80. Qiu, W. et al. 2002. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: Estradiol-adenosine hybrids with high affinity. Faseb J. 16 : 1829 1831.
81. Berube, M. & D. Poirier. 2004. Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling reactions. Org. Lett. 6 : 3127 3130.
82. Brown, W.M. et al. 2003. 17-beta-hydroxysteroid dehydrogenase type 1: Computational design of active site inhibitors targeted to the Rossmann fold. Chem. Biol. Interact. 143-144 : 481 491.
83. Gunn, D. et al. 2005. 4,5-disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg. Med. Chem. Lett. 15 : 3053 3057.
84. Bydal, P. et al. 2008. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur. J. Med. Chem. DOI :.
85. Berube, M. & D. Poirier. 2007. Chemical synthesis and in vitro biological evaluation of a phosphorylated bisubstrate inhibitor of type 3 17beta-hydroxysteroid dehydrogenase. J. Enzyme Inhib. Med. Chem. 22 : 201 211.
86. Laplante, Y., C. Rancourt & D. Poirier. 2008. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol. Cell. Endocrinol. DOI :.
87. Dykxhoorn, D.M., D. Chowdhury & J. Lieberman. 2008. RNA interference and cancer: endogenous pathways and therapeutic approaches. Adv. Exp. Med. Biol. 615 : 299 329.
88. Dalmay, T. 2008. MicroRNAs and cancer. J. Intern. Med. 263 : 366 375.
89. Guggenberger, C., D. Ilgen & J. Adamski. 2007. Functional analysis of cholesterol biosynthesis by RNA interference. J. Steroid Biochem. Mol. Biol. 104 : 105 109.
90. Day, J.M. et al. 2008. 17beta-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int. J. Cancer 122 : 1931 1940.
91. Marijanovic, Z. et al. 2003. Closing the gap: Identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol. Endocrinol. 17 : 1715 1725.
92. Luu-The, V., P. Tremblay & F. Labrie. 2005. Characterization of type 12 17beta-hydroxysteroid dehydrogenase (17beta-HSD12), an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol. Endocrinol.
93. Entchev, E.V. et al. 2008. LET-767 is required for the production of branched chain and long chain fatty acids in Caenorhabditis elegans. J. Biol. Chem. 283 : 17550 17560.
94. Baes, M. et al. 2000. Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J. Biol. Chem. 275 : 16329 16336.
95. van Grunsven, E.G. et al. 1998. Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: Resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc. Natl. Acad. Sci. USA 95 : 2128 2133.
96. Du Yan, S. et al. 2000. Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J. Biol. Chem. 275 : 27100 27109.
97. Saloniemi, T. et al. 2007. Activation of androgens by hydroxysteroid (17beta) dehydrogenase 1 in vivo as a cause of prenatal masculinization and ovarian benign serous cystadenomas. Mol. Endocrinol. 21 : 2627 2636.
98. Zhongyi, S. et al. 2007. Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids. Endocrinol. 148 : 3827 3836.
99. Rantakari, P. et al. 2008. Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene. Mol. Endocrinol. 22 : 665 675.
100. Vihko, P. et al. 2005. Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 93 : 277 283.
101. Geissler, W.M. et al. 1994. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat. Genet. 7 : 34 39.
102. Rasiah, K.K. et al. 2008. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol. Cell Endocrinol. doi :.
103. Jin, Y. & T.M. Penning. 2007. Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 47 : 263 292.
104. Biswas, M.G. & D.W. Russell. 1997. Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate. J. Biol. Chem. 272 : 15959 15966.
105. Fomitcheva, J. et al. 1998. Characterization of Ke 6, a new 17beta-hydroxysteroid dehydrogenase, and its expression in gonadal tissues. J. Biol. Chem. 273 : 22664 22671.
106. Maxwell, M.M., J. Nearing & N. Aziz. 1995. Ke 6 gene. Sequence and organization and aberrant regulation in murine polycystic kidney disease. J. Biol. Chem. 270 : 25213 25219.